Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2022 / N 1

Возможности терапевтической службы при ведении пациентов с фибрилляцией предсердий
Л.О. Минушкина

Список литературы

1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612
2. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В., Давтян К.В., Драпкина О.М., Кропачева Е.С., Кучинская Е.А., Лайович Л.Ю., Миронов Н.Ю., Мишина И.Е., Панченко Е.П., Ревишвили А.Ш., Рзаев Ф.Г., Татарский Б.А., Уцумуева М.Д., Шахматова О.О., Шлевков Н.Б., Шпектор А.В., Андреев Д.А., Артюхина Е.А., Барбараш О.Л., Галявич А.С., Дупляков Д.В., Зенин С.А., Лебедев Д.С., Михайлов Е.Н., Новикова Н.А., Попов С.В., Филатов А.Г., Шляхто Е.В., Шубик Ю.В. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):190-260. [Arakelyan MG, Bockeria LA, Vasilyeva EYu, Golitsyn SP, Golukhova EZ, Gorev MV, Davtyan KV, Drapkina OM, Kropacheva ES, Kuchinskaya EA, Layovich LYu, Mironov NYu, Mishina IE, Panchenko EP, Revishvili ASh, Rzayev FG, Tatarskiy BA, Utsumuyeva MD, Shakhmatova OO, Shlevkov NB, Shpektor AV, Andreyev DA, Artyukhina EA, Barbarash OL, Galyavich AS, Duplyakov DV, Zenin SA, Lebedev DS, Mikhaylov EN, Novikova NA, Popov SV, Filatov AG, Shlyakhto EV, Shubik YuV. 2020 Clinical guidelines for atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russian)]. DOI: 10.15829/1560-4071-2021-4594
3. Perreault S, de Denus S, White-Guay B, Côté R, Schnitzer ME, Dubé MP, Dorais M, Tardif JC. Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation. Pharmacotherapy. 2020;40(1):40-54. DOI: 10.1002/phar.2350
4. Chan YH, Lee HF, Chao TF, Wu CT, Chang SH, Yeh YH, See LC, Kuo CT, Chu PH, Wang CL, Lip GYH. Real-world comparisons of direct oral anticoagulants for stroke prevention in Asian patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Cardiovascular Drugs and Therapy. 2019;33(6):701-710. DOI: 10.1007/s10557-019-06910-z
5. Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: a Canadian retrospective cohort study. Thrombosis Research. 2021;203:121-130. DOI: 10.1016/j.thromres.2021.05.005
6. Buck J, Fromings Hill J, Martin A, Springate C, Ghosh B, Ashton R, Lee G, Orlowski A. Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review. Age and Ageing. 2021;50(4):1108-1117. DOI: 10.1093/ageing/afab024
7. Crocetti E, Cattaneo S, Bergamaschi W, De Servi S, Russo AG. Effectiveness and safety of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: results of a real-world study in a metropolitan area of Northern Italy. Journal of Clinical Medicine. 2021;10(19):4536. DOI: 10.3390/jcm10194536
8. Han S, Han S, Suh HS, Bang OY, On YK, Lee MY, Jang SW, Won MM, Park YJ, Lee JM, Kang S, Kim YH. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a nationwide, population-based study in Korea. Journal of Arrhythmia. 2021;37(5):1240-1249. DOI: 10.1002/joa3.12607
9. Ingrasciotta Y, Fontana A, Mancuso A, Ientile V, Sultana J, Uomo I, Pastorello M, Calabrò P, Andò G, Trifirò G. Comparison of direct oral anticoagulant use for the treatment of non-valvular atrial fibrillation in pivotal clinical trials vs. the real-world setting: a population-based study from Southern Italy. Pharmaceuticals (Basel). 2021;14(4):290. DOI: 10.3390/ph14040290
10. Gedikli Ö, Altay S, Ünlü S, Çakmak HA, Aşkın L, Yanık A, Beşli F, Sinan ÜY, Canpolat U, Şahin M, Pehlivanoğlu S. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: the NOAC-TURK study. The Anatolian Journal of Cardiology. 2021;25(3):196-204. DOI: 10.5152/AnatolJCardiol.2021.57635
11. Bang OY, On YK, Lee MY, Jang SW, Han S, Han S, Won MM, Park YJ, Lee JM, Choi HY, Kang S, Suh HS, Kim YH. The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: results from a real-world data analysis. PLoS One. 2020;15(11):e0242922. DOI: 10.1371/journal.pone.0242922
12. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933-2944. DOI: 10.1161/STROKEAHA.118.020232
13. Kim SM, Jeon ET, Jung JM, Lee JS. Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: a PRISMA-compliant article. Medicine (Baltimore). 2021;100(32):e26883. DOI: 10.1097/MD.0000000000026883
14. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330-1393. DOI: 10.1093/eurheartj/ehy136
15. Koretsune Y, Hoshino H, Matsuo Y, Ibuki T, Morimoto T. Comparative safety and effectiveness of apixaban vs. warfarin in oral anticoagulant-naïve Japanese patients with non-valvular atrial fibrillation – a retrospective chart review study. Circulation Journal. 2022;86(2):213-221. DOI: 10.1253/circj.CJ-21-0682
16. Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circulation. Cardiovascular Quality and Outcomes. 2021;14(2):e007230. DOI: 10.1161/CIRCOUTCOMES.120.007230
17. Lip GYH, Keshishian AV, Kang AL, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Garcia Reeves AB, Yuce H, Deitelzweig S. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. Journal of Internal Medicine. 2021;289(1):42-52. DOI: 10.1111/joim.13140
18. Shurrab M, Ko DT, McElhaney J, Henderson M, Danon A, Quinn KL, O’Donnell D, Crystal E, Newman D. Identifying factors that predict the prescription of non-vitamin K antagonist oral anticoagulants in older individuals with atrial fibrillation. Journal of the American Medical Directors Association. 2019;20(8):984-987. DOI: 10.1016/j.jamda.2019.01.131
19. Besford M, Graham S, Sammon C, Mehmud F, Allan V, Alikhan R, Ramagopalan S. Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: a CPRD-HES study. Age and Ageing. 2020;49(4):679-682. DOI: 10.1093/ageing/afaa045
20. Cavillon Decaestecker M, Ferret L, Decaestecker K, Gautier S, Verdun S, Tsogli ES. Direct oral anticoagulants and non-valvular atrial fibrillation: compliance with dose level guidelines in patients aged 80 years and over. Drugs & Aging. 2021;38(10):939-950. DOI: 10.1007/s40266-021-00883-1
21. Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Medicine. 2021;19(1):189. DOI: 10.1186/s12916-021-02067-5
22. Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, Lip GYH. Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation. Stroke. 2021;52(11):3459-3468. DOI: 10.1161/STROKEAHA.120.033338
23. Kundnani NR, Rosca CI, Sharma A, Tudor A, Rosca MS, Nisulescu DD, Branea HS, Mocanu V, Crisan DC, Buzas DR, Morariu S, Lighezan DF. Selecting the right anticoagulant for stroke prevention in atrial fibrillation. European Review for Medical and Pharmacological Sciences. 2021;25(13):4499-4505. DOI: 10.26355/eurrev_202107_26241
24. Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Park HW, Choi EK, Kim JB, Kim C, Kim J, Joung B. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). Korean Journal of Internal Medicine. 2020;35(1):99-108. DOI: 10.3904/kjim.2017.415
25. Shani M, Comaneshter D, Lustman A. Adherence to oral anticoagulant medications. The Israel Medical Association Journal. 2021;23(9):580-583.
26. Zielinski GD, van Rein N, Teichert M, Klok FA, Rosendaal FR, van der Meer FJM, Huisman MV, Cannegieter SC, Lijfering WM. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study. Pharmacoepidemiology and Drug Safity. 2021;30(8):1027-1036. DOI: 10.1002/pds.5242
27. Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Grave B, Huerta C, Martin-Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjær M, Andersen M, De Bruin ML, Souverein P, Klungel OH, Gardarsdottir H, Ibáñez L. Adherence to direct oral anticoagulants in patients with non-valvular atrial fibrillation: a cross-national comparison in six European countries (2008–2015). Frontiers in Pharmacology. 2021;12:682890. DOI: 10.3389/fphar.2021.682890
28. Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, Hung AM, Daugherty JR, Dickson A, Murray KT. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326(23):2395-2404. DOI: 10.1001/jama.2021.21222
29. Deitelzweig S, Di Fusco M, Kang A, Savone M, Mokgokong R, Keshishian A, Gutierrez C, Cappelleri JC. Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Current Medical Research and Opinion. 2021;37(6):891-902. DOI: 10.1080/03007995.2021.1897555
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]